1. The Nurse View

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Current BTK Inhibitors

5. RESONATE Ibrutinib in Previously Treated CLL

6. RESONATE-2 Ibrutinib in Previously Untreated CLL

7. Ibrutinib in R/R MCL

8. Toxicities Most Commonly Causing Ibrutinib Discontinuation in a Real-World Setting

9. Acalabrutinib: A More Selective BTK Inhibitor Phase 2 Study in CLL

10. Acalabrutinib in MCL

11. Acalabrutinib Pooled Safety Analysis (N = 610)

12. Nursing Management Tips Diarrhea

13. Nursing Management Tips Hypertension, AF, and Bleeding

14. Nursing Management Tips Myalgia and Fatigue

15. Adherence With Oral Therapy

16. Interprofessional Communication Is Essential

17. Tips for Communicating With Patients

18. Key Takeaways

19. Abbreviations

20. Abbreviations (cont)